Related Experiment Video
Updated: Sep 9, 2025

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
Inhaled nitric oxide in preterm infants with respiratory disease: a systematic review and meta-analysis
Kai Zhou1,2, Weipeng Xu3, Danrui Li3
1Faculty of Medicine, International School, Jinan University, Guangzhou, Guangdong, China.
Insights
Inhaled nitric oxide (iNO) may reduce death or bronchopulmonary dysplasia (BPD) in preterm infants. However, it increases the risk of retinopathy of prematurity, and long-term outcomes require further study.
Area of Science:
- Neonatal Medicine
- Respiratory Medicine
- Pharmacology
Background:
- Inhaled nitric oxide (iNO) is effective in term infants but has different risks/benefits in preterm infants.
- Preterm infants have unique pathophysiology requiring specific investigation for iNO.
- Further research is essential to understand iNO's role in this vulnerable population.
Purpose of the Study:
- To evaluate the short-term and long-term effects of iNO in preterm infants.
- To assess iNO's efficacy in treating respiratory failure and respiratory distress syndrome.
- To determine the safety profile of iNO in preterm neonates.
Main Methods:
- A meta-analysis of randomized controlled trials and cohort studies was performed.
- Searched major databases (PubMed, Cochrane, Scopus, Web of Science) until May 2025.
- Primary outcomes included mortality and bronchopulmonary dysplasia (BPD) at various time points.
Main Results:
- iNO use was linked to a reduced risk of death or BPD (RR 0.94) and BPD in RCTs (RR 0.91).
- Improved oxygenation index and PaO2 were observed with initial iNO concentrations of 5 ppm.
- An increased risk of retinopathy of prematurity was noted (RR 1.08), with no significant differences in other morbidities.
Conclusions:
- iNO appears to reduce the risk of death or BPD and likely reduces BPD in preterm infants.
- No significant impact on other neonatal morbidities or adverse events was found.
- Long-term respiratory and neurodevelopmental data are crucial for a comprehensive assessment of iNO in preterm infants, especially extremely low birth weight infants.
Background:
Inhaled nitric oxide (iNO) has been shown to be effective in term and near-term infants with specific respiratory diseases. The effects and potential risks of iNO differ substantially in preterm infants with special pathophysiology. Specific study in this population is necessary.
Purpose:
To assess the short-term and long-term effects of iNO in preterm infants with respiratory diseases such as respiratory failure and respiratory distress syndrome.
Methods:
We conducted a meta-analysis of randomized controlled trials and cohort studies comparing iNO with placebo or blank control in preterm infants with respiratory diseases.Databases including PubMed, the Cochrane Library, Scopus, and Web of Science were searched from their inception until May 2025. The primary outcomes were death before discharge, death at 36 weeks' postmenstrual age (PMA), bronchopulmonary dysplasia (BPD) and death or BPD.
Results:
Thirty-one trials met the inclusion criteria. iNO reduced the incidence of death or BPD (risk ratio [RR] 0.94, 95% confidence interval [CI] 0.88 to 0.99, 6 studies, 1954 infants) and BPD in the RCT subgroup (RR 0.91, 95% CI 0.84 to 0.99, 8 studies, 2196 infants).Increases of oxygenation index (Standardized mean difference (SMD) - 0.62, 95% CI - 0.81 to - 0.43, 2 studies, 441 infants) and Partial pressure of oxygen (PaO2) (SMD 0.68, 95% CI 0.49 to 0.87, 2 studies, 441 infants) of preterm infants at 5 ppm initial concentration were observed in the iNO group. The iNO group demonstrated a higher risk of retinopathy of prematurity (RR 1.08, 95% CI 1.01 to 1.16, 17 studies, 7220 infants). No significant differences were observed in other neonatal morbidities or adverse events.
Conclusions:
iNO was associated with a reduced risk of death or BPD and a probably reduction of BPD. There was no effect on other morbidities or adverse events. Data on long-term respiratory and neurodevelopment outcomes are critically needed to further evaluate NO's efficacy in preterm infants, particularly Extremely low birth weight infants.
Related Concept Videos
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Physiological Control of Respiration
Breathing, a seemingly passive process, is regulated by the respiratory center in the brainstem. This center coordinates the involuntary control of respirations, which means it occurs without conscious effort, ensuring a smooth and uninterrupted pattern.
Regulation of Ventilation
The body maintains ventilation by monitoring levels of carbon dioxide (CO2), oxygen (O2), and hydrogen ion concentration (pH) in the arterial blood. Among these factors, the level of CO2 plays a crucial...
The Respiratory System
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

